FULC FY2025 EPS Estimate Increased by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has raised its FY2025 earnings per share (EPS) estimate for Fulcrum Therapeutics from ($1.21) to ($1.18) and maintains an "Overweight" rating with a target price of $10.00.
• Fulcrum Therapeutics reported a quarterly EPS of (0.28), surpassing analysts' expectations of (0.29) by $0.01.
• Institutional ownership of Fulcrum Therapeutics is significant, with 89.83% of its shares held by institutional investors and hedge funds.

Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Stock analysts at Cantor Fitzgerald increased their FY2025 earnings per share estimates for Fulcrum Therapeutics in a research report issued to clients and investors on Wednesday, July 30th. Cantor Fitzgerald analyst K. Kluska now expects that the company will post earnings per share of ($1.18) for the year, up from their prior forecast of ($1.21). Cantor Fitzgerald has a "Overweight" rating and a $10.00 price target on the stock. The consensus estimate for Fulcrum Therapeutics' current full-year earnings is ($0.16) per share. Cantor Fitzgerald also issued estimates for Fulcrum Therapeutics' FY2026 earnings at ($1.07) EPS.

FULC has been the subject of several other reports. Royal Bank Of Canada increased their target price on Fulcrum Therapeutics from $4.00 to $5.00 and gave the company a "sector perform" rating in a research report on Wednesday, July 30th. Piper Sandler reaffirmed an "overweight" rating and set a $9.00 target price (up previously from $6.00) on shares of Fulcrum Therapeutics in a research report on Thursday, May 29th. Leerink Partnrs raised Fulcrum Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Friday, May 23rd. Leerink Partners upgraded Fulcrum Therapeutics from a "market perform" rating to an "outperform" rating and boosted their target price for the company from $4.00 to $12.00 in a research note on Friday, May 23rd. Finally, HC Wainwright upgraded Fulcrum Therapeutics from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $4.00 to $12.00 in a research note on Tuesday, July 29th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Fulcrum Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $7.57.

Fulcrum Therapeutics Price Performance

NASDAQ FULC traded down $0.08 on Friday, reaching $6.88. The stock had a trading volume of 302,273 shares, compared to its average volume of 591,949. The firm has a fifty day moving average of $7.18 and a two-hundred day moving average of $5.02. The company has a market cap of $372.14 million, a P/E ratio of -5.64 and a beta of 2.47. Fulcrum Therapeutics has a 1-year low of $2.32 and a 1-year high of $10.13.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.01.

Hedge Funds Weigh In On Fulcrum Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Personalized Indexing Management LLC boosted its holdings in shares of Fulcrum Therapeutics by 26.1% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 12,943 shares of the company's stock worth $89,000 after purchasing an additional 2,677 shares in the last quarter. Aberdeen Group plc purchased a new stake in Fulcrum Therapeutics during the 2nd quarter valued at about $404,000. Strs Ohio purchased a new stake in Fulcrum Therapeutics during the 1st quarter valued at about $263,000. Acadian Asset Management LLC boosted its holdings in Fulcrum Therapeutics by 865.0% during the 1st quarter. Acadian Asset Management LLC now owns 344,561 shares of the company's stock valued at $989,000 after acquiring an additional 308,854 shares during the period. Finally, Jane Street Group LLC boosted its holdings in Fulcrum Therapeutics by 62.1% during the 1st quarter. Jane Street Group LLC now owns 117,816 shares of the company's stock valued at $339,000 after acquiring an additional 45,157 shares during the period. 89.83% of the stock is currently owned by hedge funds and other institutional investors.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.